Associate Director, Clinical Imaging (Oncology)

Build Our Future Together

At Regeneron, we use science and innovation to develop life-changing medicines for people with serious diseases. As An Associate Director, Clinical Imaging you will lead the strategy and execution of complex early and late phase oncology imaging in clinical trials where imaging plays a key role. Imaging includes all modalities with a special focus on PET and CT. In this role, you will champion the development of imaging endpoints/biomarkers and drive the scientific imaging aspects as well as tumor response assessment of oncology clinical studies.

The successful candidate will be an independent imaging scientific leader and a member of cross-functional program teams including Regeneron clinical and preclinical colleagues as well as external academic and industry partners. This position provides excellent opportunities to develop innovative imaging endpoints and biomarkers in support of clinical development and bringing new treatment options to patients.

When & Where

Our preference for this position would be to have someone on-site in our Tarrytown, NY offices 4 days per week. However, we are also open to a remote hire for an exceptional candidate.

Discover Your Role

Create fit-for-purpose imaging biomarker strategies and work closely with research, clinical imaging and the oncology therapeutic area for the development of imaging endpoints to inform and advance the Regeneron clinical pipeline.

Prepare and present clinical imaging strategies to senior management.

Manage a complex network of stakeholders across Regeneron.

Lead, design and implement multi-modality imaging measures as endpoints for oncology therapeutic clinical studies.

Collaborate closely with Regeneron clinical teams as imaging subject matter expert to ensure optimal design and execution of imaging strategy including development of protocols, imaging manuals and charters, statistical analysis plans and clinical study reports.

Work closely with Clinical Imaging Operations and imaging contract research organizations to ensure the flawless conduct and data integrity of studies’ imaging components and endpoints.

Serve as Study Imaging Director on clinical trials focused on qualification and utilization of novel imaging biomarkers.

Design and implement novel PET, immuno-PET and other novel imaging agents/biomarkers in oncology clinical trials.

Lead the interaction with regulatory agencies for communications regarding imaging endpoints and procedures.

Lead the interaction with regulatory agencies and site ethics committees for approval of clinical imaging biomarker development studies.

This Role Requires

PhD with a minimum of 7+ years of clinical imaging experience (minimum of 5 years within oncology drug development).

Experience implementing central efficacy assessments using tumor response criteria such as RECIST 1.1, iRECIST, PCWG3, Lugano and IMWG in oncology clinical trials is required.

Successful engagement experience with regulatory agencies and the ability to champion imaging innovations and lead projects effectively.

7+ years of imaging experience in oncology drug development and clinical PET tracer development in a pharmaceutical/biotechnology setting preferred.

Experience as study scientific director of PET imaging biomarker clinical trials in Oncology preferred.

Experience with radiopharmaceuticals and applying imaging as a quantitative endpoint in clinical and preclinical studies in Oncology preferred.

Imaging CRO oversight and implementation of quality control procedures preferred.